The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
In set-up (funded)
Recruitment start date:
01/09/2017
Funder:
Bloodwise
Sponsor:
Chief Investigator:
Andrew McMillan
Recruitment target:
50
EudraCT number:
2013-004394-27
Contact details:
ctc.hovon127@ucl.ac.uk
Lay summary:
HOVON 127 Burkitt Lymphoma
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
Description
Design: HOVON 127 BL is a randomized, open-label, prospective, multicentre phase III study. All eligible patients will be randomized to receive either R-CODOX-M/R-IVAC or DA-EPOCH-R.
Treatment: Patients will receive 6 cycles of DA-EPOCH-R or 2 cycles of R-CODOX-M alternated with 2 cycles of R-IVAC. All patients will receive prophylactic intrathecal treatment and supportive care. 
Key inclusion/exclusion criteria: Patients must have a first diagnosis of high-risk Burkitt lymphoma (sporadic or HIV-associated). Patients with endemic or low-risk Burkitt lymphoma are excluded, as are any patients who have had prior treatment other than local radiation or a short-course of steroids. 
Duration of recruitment: 4 to 5 years.
Aim
The overall aim of this study is to confirm in a multicentre setting and improvement in PFS to 85% at 2 years of DA-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma, compared to 2 year PFS of 70% for the control treatment, R-CODOX-M/R-IVAC. Both regimens will also be evaluated with respect to toxicity and hospitalisation days. 
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us